{"groups":[{"description":"Patients receive 1x10\\^6 MV-NIS (TCID50) IV over 1 hour on day 1.","id":"FG000","title":"Phase I: Stage 1 (MV-NIS Alone) Dose Level 1"},{"description":"Patients receive 1x10\\^7 MV-NIS (TCID50) IV over 1 hour on day 1.","id":"FG001","title":"Phase I: Stage 1 (MV-NIS Alone) Dose Level 2"},{"description":"Patients receive 1x10\\^8 MV-NIS (TCID50) IV over 1 hour on day 1.","id":"FG002","title":"Phase I: Stage 1 (MV-NIS Alone) Dose Level 3"},{"description":"Patients receive 1x10\\^9 MV-NIS (TCID50) IV over 1 hour on day 1.","id":"FG003","title":"Phase I: Stage 1 (MV-NIS Alone) Dose Level 4"},{"description":"Patients receive 1x10\\^10 MV-NIS (TCID50) IV over 1 hour on day 1.","id":"FG004","title":"Phase I: Stage 1 (MV-NIS Alone) Dose Level 5"},{"description":"Patients receive 1x10\\^11 MV-NIS (TCID50) IV over 1 hour on day 1.","id":"FG005","title":"Phase I: Stage 1 (MV-NIS Alone) Dose Level 6"},{"description":"Patients receive 10 mg/kg cyclophosphamide IV over 30 minutes and then (Stage 1 MTD/100=10\\^7) MV-NIS (TCID50) IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)","id":"FG006","title":"Phase I: Stage 2 (MV-NIS and Cyclophosphamide) Dose Level 1"},{"description":"Patients receive 10 mg/kg cyclophosphamide IV over 30 minutes and then 3 x 10\\^7 MV-NIS (TCID50) IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)","id":"FG007","title":"Phase I: Stage 2 (MV-NIS and Cyclophosphamide) Dose Level 2"},{"description":"Patients receive 10 mg/kg cyclophosphamide IV over 30 minutes and then 9 x 10\\^7 MV-NIS (TCID50) IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)","id":"FG008","title":"Phase I: Stage 2 (MV-NIS and Cyclophosphamide) Dose Level 3"},{"description":"Cohort A patients (relapsed or refractory multiple myeloma who have exhausted all therapeutic options) receive 650 mg Acetaminophen and 50 mg Benadryl orally 30 minutes prior to MV-NIS then receive MV-NIS IV over 1 hour on day 1.","id":"FG009","title":"Phase II (Acetaminophen + Benadryl + MV-NIS) Cohort A"},{"description":"Cohort B patients (relapsing from VGPR or CR and have not\n\n\\> received myeloma directed therapy for at least 12 weeks) receive 650 mg Acetaminophen and 50 mg Benadryl orally 30 minutes prior to MV-NIS then receive MV-NIS IV over 1 hour on day 1.","id":"FG010","title":"Phase II (Acetaminophen + Benadryl + MV-NIS) Cohort B"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}],"type":"Failed to complete the initial therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"}],"type":"Patient withdrawal prior to treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"7"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"12"},{"groupId":"FG010","numSubjects":"4"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"11"},{"groupId":"FG010","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Phase I: INITIALLY CLOSED ON 12/17/2009 AND STAGE 2 BEGUN; HOWEVER, DUE TO NEW MANUFACTURING CAPABILITIES, STAGE 1 RE-OPENED ON October 13, 2011, FOR DOSE LEVELS 5 AND 6. Phase II: Accrual to Cohort A closed due to failed interim analysis. Cohort B closed due to lack of accrual."}